Gavi news release
New TB vaccines, which are expected to become available from 2029, could help save up to an estimated 7.3 million lives between 2030 and 2050, unlocking up to US$ 135 billion in economic benefits across low- and middle-income countries, according to new analysis on their potential impact. These benefits highlight the potential for new TB vaccines to become one of the most impactful new immunisation tools in decades, representing a breakthrough technology in fighting the world’s deadliest infectious disease.
Nevertheless, in its Early Market Shaping Roadmap for Novel TB Vaccines, Gavi, the Vaccine Alliance (Gavi) warns that action is required now to prepare governments and vaccine manufacturers for the vaccines’ arrival. According to the Roadmap, demand for the vaccines among low-income countries and middle-income countries could reach, on average, 86 million vaccination courses per year, with greater demand in the early years as high-burden countries seek to expand protection across multiple age groups in high-risk areas.
Read the full news release here.
For more TB updates, check out the TB CAB Weekly Newsletter (Issue #24, 20 September 2026).
The newsletter is brought to you by the Global TB Community Advisory Board (TB CAB) with the support of Treatment Action Group (TAG) and the European AIDS Treatment Group (EATG). Subscribe to the newsletter here.
Source : Gavi
Related HIV and Co-Infections News
-
Boston University School of Public Health | TB preventive treatment wanes after one year in high-burden countries, but lasts for at least 8 to 13 years in low- and medium-burden countries
-
[Statements] Advocates react to Gilead–PAHO lenacapavir agreement for Latin America and the Caribbean
-
Health Policy Watch | Controversy, secrecy and suffering after year one of the America First Global Health Strategy
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.